Celta Square announced on the 31st that it had attracted a total of 9.2 billion won in Series A investment from KB Investment, Korea Investment Partners, Yuanta Investment, SJ Investment Partners, and Zenaxis Investment.
Celta Square is a company that provides full-cycle drug monitoring solutions utilizing artificial intelligence (AI) technology. This investment is a result of reflecting the contemporary need for commercialization of AI technology and digital solutions in the pharmaceutical and bio markets. Celta Square’s outstanding technological prowess and expertise in the field of drug monitoring have been highly evaluated by investors.
The AI-based drug monitoring solution developed by Celta Square can be used in all drug monitoring practices, and is contributing to improving the productivity and accuracy of the work.
Representative solutions include 'SELTA-WAVE', a safety data entry automation solution, 'SELTA-LITUS', a literature search automation solution, 'SELTA-OCTO', an AI-based MedDRA coding solution, and 'SELTA-TUBE', an analysis and table automation solution for product updates. These solutions are dramatically improving the work efficiency and data quality of pharmacovigilance experts by applying the latest AI technology. In particular, SELTA-WAVE plans to release an upgraded version that reflects customer feedback in the first half of 2025.
Shin Min-kyung, CEO of Celta Square, said, “Through this investment, we have once again proven our technological prowess and marketability,” and expressed her aspirations, saying, “We will accelerate our entry into the global market and further increase the utilization of artificial intelligence technology in the pharmaceutical and bio fields.”
An official who participated in the investment explained the background of the investment, saying, “Celta Square’s AI technology provides a clear point of differentiation in the market by innovatively improving the complex drug monitoring process,” and “In particular, we evaluated that it has very high growth potential in the global pharmaceutical and bio markets.”
- See more related articles
You must be logged in to post a comment.